AR045080A1 - Compuestos de cianopirrolididas, procedimiento para su preparacion y su uso como medicamentos - Google Patents

Compuestos de cianopirrolididas, procedimiento para su preparacion y su uso como medicamentos

Info

Publication number
AR045080A1
AR045080A1 ARP040102609A ARP040102609A AR045080A1 AR 045080 A1 AR045080 A1 AR 045080A1 AR P040102609 A ARP040102609 A AR P040102609A AR P040102609 A ARP040102609 A AR P040102609A AR 045080 A1 AR045080 A1 AR 045080A1
Authority
AR
Argentina
Prior art keywords
alkylene
heterocyclyl
aryl
cycloalkyl
alkyl
Prior art date
Application number
ARP040102609A
Other languages
English (en)
Spanish (es)
Original Assignee
Aventis Pharma Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from DE10333935A external-priority patent/DE10333935A1/de
Priority claimed from DE102004019276A external-priority patent/DE102004019276A1/de
Application filed by Aventis Pharma Gmbh filed Critical Aventis Pharma Gmbh
Publication of AR045080A1 publication Critical patent/AR045080A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A61P39/06—Free radical scavengers or antioxidants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
    • A61P5/50—Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/12—Antidiuretics, e.g. drugs for diabetes insipidus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Diabetes (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Chemistry (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Biochemistry (AREA)
  • Toxicology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
ARP040102609A 2003-07-25 2004-07-22 Compuestos de cianopirrolididas, procedimiento para su preparacion y su uso como medicamentos AR045080A1 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DE10333935A DE10333935A1 (de) 2003-07-25 2003-07-25 Neue bicyclische Cyanoheterocyclen, Verfahren zu ihrer Herstellung und ihre Verwendung als Arzneimittel
DE102004019276A DE102004019276A1 (de) 2004-04-21 2004-04-21 Neue Cyanopyrrolidide, Verfahren zu ihrer Herstellung und ihre Verwendung als Arzneimittel

Publications (1)

Publication Number Publication Date
AR045080A1 true AR045080A1 (es) 2005-10-12

Family

ID=34117368

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP040102609A AR045080A1 (es) 2003-07-25 2004-07-22 Compuestos de cianopirrolididas, procedimiento para su preparacion y su uso como medicamentos

Country Status (13)

Country Link
EP (1) EP1651649B1 (cg-RX-API-DMAC10.html)
JP (1) JP2006528601A (cg-RX-API-DMAC10.html)
AR (1) AR045080A1 (cg-RX-API-DMAC10.html)
AT (1) ATE490256T1 (cg-RX-API-DMAC10.html)
AU (1) AU2004261364A1 (cg-RX-API-DMAC10.html)
BR (1) BRPI0412900A (cg-RX-API-DMAC10.html)
CA (1) CA2534267A1 (cg-RX-API-DMAC10.html)
DE (1) DE502004011957D1 (cg-RX-API-DMAC10.html)
IL (1) IL173204A0 (cg-RX-API-DMAC10.html)
MX (1) MXPA06000634A (cg-RX-API-DMAC10.html)
PE (1) PE20050249A1 (cg-RX-API-DMAC10.html)
TW (1) TW200524936A (cg-RX-API-DMAC10.html)
WO (1) WO2005012308A1 (cg-RX-API-DMAC10.html)

Families Citing this family (44)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DOP2006000008A (es) 2005-01-10 2006-08-31 Arena Pharm Inc Terapia combinada para el tratamiento de la diabetes y afecciones relacionadas y para el tratamiento de afecciones que mejoran mediante un incremento de la concentración sanguínea de glp-1
GB0526291D0 (en) 2005-12-23 2006-02-01 Prosidion Ltd Therapeutic method
PE20071221A1 (es) 2006-04-11 2007-12-14 Arena Pharm Inc Agonistas del receptor gpr119 en metodos para aumentar la masa osea y para tratar la osteoporosis y otras afecciones caracterizadas por masa osea baja, y la terapia combinada relacionada a estos agonistas
JP2010500300A (ja) 2006-08-08 2010-01-07 サノフィ−アベンティス アリールアミノアリール−アルキル−置換イミダゾリジン−2,4−ジオン、それらの製造法、それらの化合物を含有する薬剤、およびそれらの使用
DE102007005045B4 (de) 2007-01-26 2008-12-18 Sanofi-Aventis Phenothiazin Derivate, Verfahren zu ihrer Herstellung und ihre Verwendung als Arzneimittel
EP2025674A1 (de) 2007-08-15 2009-02-18 sanofi-aventis Substituierte Tetrahydronaphthaline, Verfahren zu ihrer Herstellung und ihre Verwendung als Arzneimittel
EP2146210A1 (en) 2008-04-07 2010-01-20 Arena Pharmaceuticals, Inc. Methods of using A G protein-coupled receptor to identify peptide YY (PYY) secretagogues and compounds useful in the treatment of conditions modulated by PYY
WO2010003624A2 (en) 2008-07-09 2010-01-14 Sanofi-Aventis Heterocyclic compounds, processes for their preparation, medicaments comprising these compounds, and the use thereof
WO2010068601A1 (en) 2008-12-08 2010-06-17 Sanofi-Aventis A crystalline heteroaromatic fluoroglycoside hydrate, processes for making, methods of use and pharmaceutical compositions thereof
AR077642A1 (es) 2009-07-09 2011-09-14 Arena Pharm Inc Moduladores del metabolismo y el tratamiento de trastornos relacionados con el mismo
SG178880A1 (en) 2009-08-26 2012-04-27 Sanofi Sa Novel crystalline heteroaromatic fluoroglycoside hydrates, pharmaceuticals comprising these compounds and their use
WO2011107494A1 (de) 2010-03-03 2011-09-09 Sanofi Neue aromatische glykosidderivate, diese verbindungen enthaltende arzneimittel und deren verwendung
JP2013523819A (ja) 2010-04-06 2013-06-17 アリーナ ファーマシューティカルズ, インコーポレイテッド Gpr119レセプターのモジュレーターおよびそれに関連する障害の処置
EP2582709B1 (de) 2010-06-18 2018-01-24 Sanofi Azolopyridin-3-on-derivate als inhibitoren von lipasen und phospholipasen
US8530413B2 (en) 2010-06-21 2013-09-10 Sanofi Heterocyclically substituted methoxyphenyl derivatives with an oxo group, processes for preparation thereof and use thereof as medicaments
TW201215387A (en) 2010-07-05 2012-04-16 Sanofi Aventis Spirocyclically substituted 1,3-propane dioxide derivatives, processes for preparation thereof and use thereof as a medicament
TW201215388A (en) 2010-07-05 2012-04-16 Sanofi Sa (2-aryloxyacetylamino)phenylpropionic acid derivatives, processes for preparation thereof and use thereof as medicaments
TW201221505A (en) 2010-07-05 2012-06-01 Sanofi Sa Aryloxyalkylene-substituted hydroxyphenylhexynoic acids, process for preparation thereof and use thereof as a medicament
CN103221410B (zh) 2010-09-22 2017-09-15 艾尼纳制药公司 Gpr119受体调节剂和对与其相关的障碍的治疗
US8809324B2 (en) 2011-03-08 2014-08-19 Sanofi Substituted phenyl-oxathiazine derivatives, method for producing them, drugs containing said compounds and the use thereof
EP2766349B1 (de) 2011-03-08 2016-06-01 Sanofi Mit carbozyklen oder heterozyklen substituierte oxathiazinderivate, verfahren zu deren herstellung, diese verbindungen enthaltende arzneimittel und deren verwendung
WO2012120054A1 (de) 2011-03-08 2012-09-13 Sanofi Di- und trisubstituierte oxathiazinderivate, verfahren zu deren herstellung, ihre verwendung als medikament sowie sie enthaltendes arzneimittel und deren verwendung
WO2012120056A1 (de) 2011-03-08 2012-09-13 Sanofi Tetrasubstituierte oxathiazinderivate, verfahren zu deren herstellung, ihre verwendung als medikament sowie sie enthaltendes arzneimittel und deren verwendung
EP2683704B1 (de) 2011-03-08 2014-12-17 Sanofi Verzweigte oxathiazinderivate, verfahren zu deren herstellung, ihre verwendung als medikament sowie sie enthaltendes arzneimittel und deren verwendung
WO2012120055A1 (de) 2011-03-08 2012-09-13 Sanofi Di- und trisubstituierte oxathiazinderivate, verfahren zu deren herstellung, ihre verwendung als medikament sowie sie enthaltendes arzneimittel und deren verwendung
EP2683703B1 (de) 2011-03-08 2015-05-27 Sanofi Neue substituierte phenyl-oxathiazinderivate, verfahren zu deren herstellung, diese verbindungen enthaltende arzneimittel und deren verwendung
EP2683698B1 (de) 2011-03-08 2017-10-04 Sanofi Mit adamantan- oder noradamantan substituierte benzyl-oxathiazinderivate, diese verbindungen enthaltende arzneimittel und deren verwendung
US8846666B2 (en) 2011-03-08 2014-09-30 Sanofi Oxathiazine derivatives which are substituted with benzyl or heteromethylene groups, method for producing them, their use as medicine and drug containing said derivatives and the use thereof
US20140018371A1 (en) 2011-04-01 2014-01-16 Arena Pharmaceuticals, Inc. Modulators Of The GPR119 Receptor And The Treatment Of Disorders Related Thereto
EP2697241B1 (en) 2011-04-13 2019-06-12 Gilead Sciences, Inc. 1'-substituted pyrimidine n-nucleoside analogs for antiviral treatment
WO2012145361A1 (en) 2011-04-19 2012-10-26 Arena Pharmaceuticals, Inc. Modulators of the gpr119 receptor and the treatment of disorders related thereto
WO2012145604A1 (en) 2011-04-22 2012-10-26 Arena Pharmaceuticals, Inc. Modulators of the gpr119 receptor and the treatment of disorders related thereto
WO2012145603A1 (en) 2011-04-22 2012-10-26 Arena Pharmaceuticals, Inc. Modulators of the gpr119 receptor and the treatment of disorders related thereto
WO2012170702A1 (en) 2011-06-08 2012-12-13 Arena Pharmaceuticals, Inc. Modulators of the gpr119 receptor and the treatment of disorders related thereto
WO2013037390A1 (en) 2011-09-12 2013-03-21 Sanofi 6-(4-hydroxy-phenyl)-3-styryl-1h-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors
EP2760862B1 (en) 2011-09-27 2015-10-21 Sanofi 6-(4-hydroxy-phenyl)-3-alkyl-1h-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors
WO2013055910A1 (en) 2011-10-12 2013-04-18 Arena Pharmaceuticals, Inc. Modulators of the gpr119 receptor and the treatment of disorders related thereto
CN105142621A (zh) 2012-10-24 2015-12-09 国家健康科学研究所 用于预防或治疗糖尿病和促进β-细胞存活的TPL2激酶抑制剂
WO2014074668A1 (en) 2012-11-08 2014-05-15 Arena Pharmaceuticals, Inc. Modulators of gpr119 and the treatment of disorders related thereto
CN107683135A (zh) 2015-03-09 2018-02-09 因特克林医疗有限公司 用于治疗非酒精性脂肪肝疾病和/或脂肪营养不良的方法
EP3273981B1 (en) 2015-03-24 2020-04-29 INSERM - Institut National de la Santé et de la Recherche Médicale Method and pharmaceutical composition for use in the treatment of diabetes
AU2018249822A1 (en) 2017-04-03 2019-10-31 Coherus Biosciences Inc. PPArgamma agonist for treatment of progressive supranuclear palsy
BR112021002207A2 (pt) 2018-08-10 2021-05-04 Diapin Therapeutics, Llc tri-peptídeos e tratamento de distúrbios metabólicos, cardiovasculares e inflamatórios
CN109867679B (zh) * 2019-04-11 2021-11-30 杭州瀚康生物医药科技有限公司 盐酸吡西卡尼中间体的制备方法

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2997894B2 (ja) * 1990-11-07 2000-01-11 株式会社三和化学研究所 循環器系疾患の予防及び治療剤
AU1910299A (en) * 1997-12-18 1999-07-05 Eli Lilly And Company Peptidomimetic template-based combinatorial libraries

Also Published As

Publication number Publication date
JP2006528601A (ja) 2006-12-21
BRPI0412900A (pt) 2006-10-31
TW200524936A (en) 2005-08-01
IL173204A0 (en) 2006-06-11
AU2004261364A1 (en) 2005-02-10
PE20050249A1 (es) 2005-06-01
DE502004011957D1 (de) 2011-01-13
WO2005012308A1 (de) 2005-02-10
ATE490256T1 (de) 2010-12-15
EP1651649B1 (de) 2010-12-01
EP1651649A1 (de) 2006-05-03
CA2534267A1 (en) 2005-02-10
MXPA06000634A (es) 2006-08-23

Similar Documents

Publication Publication Date Title
AR043155A1 (es) Derivados sustituidos de hexahidro-pirazino[1,2-a] pirimidin-4,7-diona, procedimientos para su preparacion y su uso como medicamentos
PE20140407A1 (es) Nuevos compuestos triciclicos
AR070207A1 (es) Derivados biciclicos de carboxamidas aza- biciclicas su preparacion y su aplicacion terapeutica
PE20110122A1 (es) COMPUESTOS DERIVADOS DE 9H-PIRROLO[2,3-b:5,4-c]DIPIRIDIN-6-(PIRIDIN-3-IL) COMO INHIBIDORES DE LAS CINASA Pim
PE20090248A1 (es) Moduladores de beta-amiloide
PE20081612A1 (es) Analogos de las pterinas
PE20081844A1 (es) DERIVADOS DE INDOL-3-IL-CARBONIL-AZASPIROPIPERIDINA COMO ANTAGONISTAS DEL RECEPTOR V1a
AR054621A1 (es) 1-aril-4-ciclopropilpirazoles sustituidos
CO6501182A2 (es) Derivados de 1-heterociclil-1,5-dihidro-pirazolo[3,4-d]pirimidin-4-ona y su uso como moduladores de pde9a
AR040477A1 (es) Benzoilureas heterociclicamente sustituidas, procedimiento para su preparacion y su uso como farmacos
CO6290658A2 (es) Derivados de azetidina y ciclobutano como inhibidores de jack
AR085110A1 (es) Derivados de 7-azaindol
AR085406A1 (es) Oxazinopteridinas y oxazinopteridinonas n-sustituidas
PE20120031A1 (es) Compuestos aril metil benzoquinazolinona como moduladores alostericos positivos del receptor m1
AR043154A1 (es) Derivados sustituidos con nitrogeno de hexahidro-pirazino[1,2-a] pirimidin-4,7-diona, procedimientos para su preparacion y su uso como medicamentos
PE20120172A1 (es) Compuestos heterociclicos fusionados que contiene nitrogeno como inhibidores de la produccion de beta-amiloide
PE20091669A1 (es) Benzofuropirimidinonas
DOP2010000351A (es) Activadores de glucoquinasa
AR060984A1 (es) Derivados de imidazo[1,5-a]pirido[3,2-e]pirazinas,y su uso en el sistema nervioso central como inhibidores de la fosfodiesterasa 10.
CO6210701A2 (es) Derivados de amidas del acido 6,7-dihidro-5h-imidazo[1,2-a]imidazol-3-carboxilico
AR082015A1 (es) Derivados de metoxifenilo heterociclicamente sustituidos con un grupo oxo, procedimientos para su preparacion y uso de los mismos como medicamentos
GT200600430A (es) Compuestos de carboxiamina y metodos de uso de los mismos
PE20212071A1 (es) Pirazolopiridinas y triazolopiridinas como inhibidores de a2a / a2b
NI201000011A (es) Derivados de pirimidina 934.
CO6410299A2 (es) Derivados de triazolo [4,3-b] pridazina y sus usos para el cáncer de próstata

Legal Events

Date Code Title Description
FB Suspension of granting procedure